On December 13, 2022, the COVID-19 vaccine developer Moderna and pharmaceutical company Merck announced a progressive advancement in forming vaccination for melanoma, known as one of the most fatal types of skin cancer.
Moderna is collaborating with Merck to study and create a feasible melanoma vaccine among patients who had surgery for their cancer. The study combines an mRNA vaccine strategy and a drug to expedite the immune system and bring favorable results for melanoma patients.
With the vaccine and Merck's immunotherapy Keytruda, the team saw a notable difference in the patient's survival rate. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” shared Moderna CEO Stephane Bancel with CNBC. Phase 3 is typically the most costly stage of research before the drug gets officially approved.
https://healthnews.com/news/moderna-and-mercks-skin-cancer-vaccine-trial-shows-favorable-results/
unknownx500
